Menu Search
Equities

Malaysian Genomics Resource Centre Bhd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MGRC:KLS

Malaysian Genomics Resource Centre Bhd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (MYR)0.22
  • Today's Change0.02 / 10.00%
  • Shares traded200.00
  • 1 Year change-32.31%
  • Beta0.0495
Data delayed at least 15 minutes, as of Feb 12 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Malaysian Genomics Resource Centre Berhad is a Malaysia-based genomics and biopharmaceutical company. The Company is engaged in enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. Its services include Genome Sequencing Services, Genome Analysis Services, Genetic Screening Services, and Cancer Immunotherapy. Its whole genome sequencing (WGS) is a comprehensive technique used to determine the complete deoxyribonucleic acid (DNA) sequence of an individual’s entire genome. Its flagship product, the Dtect genetic screening tests, inspects an individual’s DNA for markers associated with genetic variations that influence various biological processes. Its CAR T-cell immunotherapy focuses on the immune system’s ability to detect and eliminate cancer cells. Its Genome analysis includes services, such as bioinformatics, trait analysis, and trio sequencing.

  • Revenue in MYR (TTM)6.67m
  • Net income in MYR-1.25m
  • Incorporated2004
  • Employees35.00
  • Location
    Malaysian Genomics Resource Centre Bhd8F Jalan Teknologi 3/6, Taman Sains SelaPETALING JAYA 47810MalaysiaMYS
  • Phone+60 378900015
  • Fax+60 361503232
  • Websitehttps://www.mgrc.com.my/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.